NIPER Raebareli signs MoU with Roche Pharma India to strengthen Research (See 'Corp Brief') Sonowal interacts with Crew; calls Seafarers 'unsung heroes of Global Trade' (See 'Corp Brief') ITDC, Ministry of Tribal Affairs inaugurate Capacity Building Program for Tribal Homestay Owners (See 'Corp Brief') Food Processing Industry Must Align with Nutrition Security Goals (See 'Corp Brief') Trade Marks - Quasi-judicial authorities exercising statutory powers under the Trade Marks Act must pass a reasoned & speaking order after considering evidences & submissions placed; failure to do so amounts to abdication of these functions: HC (See 'Legal Desk') Raksha Mantri to inaugurate Conclave on 'Advanced Manufacturing Technologies' (See 'Corp Brief') Govt strengthens Institutional Credit Framework for Agriculture and Allied Sectors (See 'Corp Brief') Centre encouraging cash crops in place of tobacco: Chouhan (See 'Corp Brief') Over 1 Lakh Startups have at least One-Woman Director: Govt (See 'Corp Brief') PMLA - Allegations of mala fide cannot be accepted without specific evidence against ED officials; search authorization & consequent actions are distinct from scheduled offences u/s 3 of PMLA: HC (See 'Legal Desk') MoSPI has initiated measures to strengthen accountability in data collection (See 'Corp Brief') Govt expands Youth Skill Development through NSS, Skill India Mission and NEP Initiatives (See 'Corp Brief') Govt boosts Renewable Energy Awareness Nationwide (See 'Corp Brief') Misc - Doctrine of lis pendens u/s 52 of TOPA is not applicable to transfer of property that occurs before institution of suit concerning that property, especially when transferor is not party to subsequent suit: HC (See 'Legal Desk') CCI organises 11th Edition of National Conference on Economics of Competition Law (See 'Corp Brief') India submits Report on Implementation of Nagoya Protocol for Biodiversity (See 'Corp Brief') MSME Champion Scheme progressing well towards achieving its objectives (See 'Corp Brief') A&C - Law provides award creditor with additional option to file for execution directly in court where assets are located, but this does not extinguish jurisdiction of Seat Court: HC (See 'Legal Desk') IICA convenes 5th Inter-Ministerial Consultation on Responsible Business Conduct and ESG (See 'Corp Brief') BCCL Organizes Interaction with NRS Linkage and CIL SWMA e-Auction Consumers (See 'Corp Brief') Madnaviya & Kumaraswamy lay foundation of indoor sports complex in Karnataka (See 'Corp Brief') A&C - Juridical seat of arbitration is determinative factor for conferring exclusive supervisory jurisdiction on court: HC (See 'Legal Desk') India's progress in reducing Tuberculosis Incidence has Outpaced Global Average: Nadda (See 'Corp Brief') Rs 100 crore sanctioned for Integrated Aqua Park Project in Anantnag (See 'Corp Brief') Reddy inaugurates Multiple Projects in WCL (See 'Corp Brief') PMLA - If mortgaged properties are to be auctioned by bank or settled with borrower which may result in concealment, it would be only of those properties which was considered to be assets disproportionate to known source: SAFEMA (See 'Legal Desk') Supreme Court Clears Path For Single Insolvency Proceedings Against Linked Group Companies (See CORP EINSICHT)

Print

NPPA monitors prices of scheduled & non-scheduled medicines

Published: Jul 30, 2024

By TIOLCorplaws News Service

NEW DELHI, JULY 30, 2024: AS per the provisions of Drugs (Prices Control) Order, 2013 (DPCO, 2013), formulations listed in Schedule-I of the DPCO are defined as scheduled formulation under section 2(1)(zb) of DPCO, 2013. Formulations not included in Schedule-I are defined under Para 2(1)(v) of DPCO, 2013 as non-scheduled formulation. Thus, both schedule and non-schedule drugs are covered under DPCO, 2013. 

As per the extant provisions of DPCO, 2013, the ceiling prices of scheduled medicines are revised annually on the basis of Wholesale Price Index (WPI) (all commodities) for preceding calendar year by National Pharmaceutical Pricing Authority (NPPA), on or before 1st April of every year and is notified by the Government on the 1st day of April every year. The details of price fixed by NPPA are available at NPPA's website i.e. nppaindia.nic.in.  In case of non-scheduled formulation (branded or generic), as per para 20 of DPCO, 2013, no manufacturers can increase Maximum Retail Price (MRP) by more than 10% of MRP during preceding 12 months.  The maximum permissible increase in prices, as per the provisions of DPCO, 2013 for scheduled and non-scheduled drugs may or may not be availed by their respective manufacturers based on commercial considerations and market dynamics.

Under the Drugs and Cosmetics Act, 1945 and Rules thereunder, manufacturers of drugs are required to comply with conditions of manufacturing licence and the requirements of Good Manufacturing Practices (GMP).  As per the Drugs Rules, 1945, the manufacturing, testing, labeling, packaging, storage and distribution are required to be carried out in compliance with the conditions of license including the Good manufacturing practices (GMP) prescribed under the Schedule M of the Drugs Rules, 1945. In case of violation, the Licensing Authority is empowered to take action as per the said Act and Rules.

NPPA monitors the prices of scheduled as well as non-scheduled medicines under DPCO, 2013.  Action is taken against companies, found selling formulations at prices higher than the permissible price, and the overcharged amount is recovered from the company as per the relevant provisions of the DPCO, 2013. During the financial year 2023-24, Rs. 72.73 crore was recovered from the defaulting companies.

This information was given by the Union Minister of State for Chemicals and Fertilizers Anupriya Patel in Rajya Sabha in reply to a question today.

TIOL CORP SEARCH

TIOL GROUP WEBSITES

taxindiaonline
taxindiainternational
tioltube
TKF
TIOLawards
A TIOL Website. Copyright © 2025 TIOLcorplaws.com All rights reserved.